Azitra, Inc. (AZTR) Stock Score, Valuation & Financial Research

Azitra, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for AZTR

Azitra, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.14. These figures are a research snapshot, not a buy or sell recommendation.

What Azitra, Inc. does

Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Azitra is a clinical-stage biopharmaceutical company that generates no commercial revenue. It operates by investing in research and development to create proprietary platforms of engineered topical live biotherapeutics for dermatological diseases, relying on capital raises to fund its operations.

Products and services

  • The company is developing a pipeline of precision dermatology therapies, including its lead program ATR-12, which utilizes an engineered strain of Staphylococcus epidermidis.

Brands and product families

  • ATR-12 — Lead clinical program using an engineered strain of S. epidermidis. Source

Customer types

Patients with dermatological diseases.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct its clinical trials and IND-enabling studies. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies — The company competes with other biopharmaceutical and biotechnology companies developing therapies for skin conditions, including those using live biotherapeutics or traditional pharmaceutical approaches. Source

Business strengths to evaluate

  • Proprietary platform of engineered topical live biotherapeutics Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Clinical trial failure and regulatory approval uncertainty Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

AZTR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.14
Market capitalization:
1.48M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -12.27M
Free cash flow:
USD -11.41M
Cash:
USD 6.73M
Total debt:
USD 410.05K
EPS:
USD -1.30

What stands out

  • Free cash flow is USD -11.41M, negative for the stored period.
  • The balance sheet shows USD 6.73M of cash versus USD 410.05K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 6.32M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for AZTR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can AZTR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is AZTR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for AZTR to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of AZTR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research AZTR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.